Sir Rory Collins | |
|---|---|
| Born | Rory Edwards Collins (1955-01-03)3 January 1955 (age 70)[2] |
| Alma mater | |
| Known for | UK Biobank[3][4][5] |
| Awards |
|
| Scientific career | |
| Fields | |
| Institutions | University of Oxford |
| Website | www |
Sir Rory Edwards CollinsFMedSciFRS[1] (born 3 January 1955) is a British physician who is Professor of Medicine andEpidemiology at theClinical Trial Service Unit within theUniversity of Oxford, the head of theNuffield Department of Population Health and a Fellow ofGreen Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment ofheart attacks, othervascular disease, andcancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses").[6][7][8] Since September 2005, he has been the Principal Investigator and Chief Executive of theUK Biobank,[3][4][5] aprospective study of 500,000 British people aged 40–69 at recruitment.
Collins was educated atDulwich College[2] and studied Medicine atSt Thomas's Hospital Medical School, part of theUniversity of London (1974–1980), and Statistics atGeorge Washington University from 1976 to 1977 and theUniversity of Oxford from 1982 to 1983.[citation needed]
Since 1985, Collins has been co-director with SirRichard Peto of theUniversity of Oxford's Clinical Trial Services and Epidemiological Studies units. In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by theBritish Heart Foundation. Since September 2005, he has also been acting as the Principal Investigator and Chief Executive of theUK Biobank,[3][4][5] a prospective study of 500,000 British people, aged 40–69 at recruitment.
Collins' work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer.[9]
He has created and led large studies that transformedstatins from esoteric drugs forfamilial hypercholesterolaemia into widely-usedgenerics that prevent millions of heart attacks and ischaemic strokes annually. His largeplacebo-controlled trials and worldwide Cholesterol Treatment Trialists' meta-analyses confirmed that statins reduce the risk of heart attack, discovered that they reduce the risk ofstroke, and demonstrated their safety and efficacy in many different types of patient.[1] His research has been funded by theMedical Research Council (MRC).[10]
Collins wasknighted in the2011 New Year Honours for services to science.[11] He was elected as a Fellow of theAcademy of Medical Sciences in 2004 and aFellow of the Royal Society (FRS) in 2015.[1] Collins was included in Time's 2024 list of 100 most influential people in health.[12]
"All text published under the heading 'Biography' on Fellow profile pages is available underCreative Commons Attribution 4.0 International License.” --"Royal Society Terms, conditions and policies". Archived from the original on 25 September 2015. Retrieved9 March 2016.
{{cite web}}: CS1 maint: bot: original URL status unknown (link)
Authority control databases: Academics |
|---|
 | This United Kingdom biographical article related to medicine is astub. You can help Wikipedia byexpanding it. |